LEADER 00889nam0-22002891i-450- 001 990007516670403321 005 20051116113035.0 035 $a000751667 035 $aFED01000751667 035 $a(Aleph)000751667FED01 035 $a000751667 100 $a20030814d1930----km-y0itay50------ba 101 0 $ager 102 $aDE 105 $a--------001yy 200 1 $aItalien im ostlichen Mittelmeer$eeine politische Studie uber die Bedeutung der anatolischen Kusteninseln$fIbrahim Seyfullah 210 $aBerlin$cVowinckel$d1930 215 $aXI, 91 p.$cill.$d20 cm 225 1 $aBeihefte zur Zeitschrift fur Geopolitik$v7 700 1$aSeyfullah,$bIbrahim$0271599 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990007516670403321 952 $aE-03-033$bIst. s.i.$fILFGE 959 $aILFGE 996 $aItalien im ostlichen Mittelmeer$9682959 997 $aUNINA LEADER 01054nam--2200337---450- 001 990001070110203316 005 20020417135002.0 035 $a000107011 035 $aUSA01000107011 035 $a(ALEPH)000107011USA01 035 $a000107011 100 $a20020417d1982----km-y0itay0103----ba 101 $ager 102 $aDE 105 $a||||||||001yy 200 1 $aDualisierende Komplexe in der lokalen Algebra und Buchsbaum - Ringe$fPeter Schenzel 210 $aBerlin$cSpringer verlag$dc1982 215 $aVII, 160 o.$cill.$d24 cm 225 2 $aLecture notes in mathematics$v907 410 $12001$aLecture notes in mathematics$v907 676 $a512.53 700 1$aSCHENZEL,$BPeter$058453 801 0$aIT$bsalbc$gISBD 912 $a990001070110203316 951 $a510 LNM 907$b2830 CBS$c510$D00110010 959 $aBK 969 $aSCI 979 $aPATTY$b90$c20020417$lUSA01$h1350 979 $aPATRY$b90$c20040406$lUSA01$h1714 996 $aDualisierende komplexe in der lokalen algebra und Buchsbaum-ringe$980569 997 $aUNISA LEADER 04625nam 2201213z- 450 001 9910619467203321 005 20221025 010 $a3-0365-5281-2 035 $a(CKB)5670000000391602 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/93194 035 $a(oapen)doab93194 035 $a(EXLCZ)995670000000391602 100 $a20202210d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aBrain-Targeted Drug Delivery 210 $cMDPI - Multidisciplinary Digital Publishing Institute$d2022 215 $a1 online resource (260 p.) 311 08$a3-0365-5282-0 330 $aBrain diseases currently affect one in six people worldwide; they include a wide range of neurological diseases, from Alzheimer's and Parkinson's diseases to epilepsy, brain injuries, brain cancer, neuroinfections, and strokes. The treatment of these diseases is complex and limited due to the presence of the blood-brain barrier (BBB), which covers the entirety of the brain. The BBB not only has the function of protecting the brain from harmful substances; it is also a metabolic barrier and a transport regulator of nutrients/serum factors/neurotoxins. Knowing these characteristics when it comes to the treatment of brain diseases makes it easier to understand the lack of efficacy of therapeutic drugs, resulting from the innate resistance of the BBB to permeation. To overcome this limitation, drug delivery systems based on nanotechnology/microtechnology have been developed. Brain-targeted drug delivery enables targeted therapy with a higher therapeutic efficacy and fewer side effects because it targets moieties present in the drug delivery systems. 606 $aTechnology: general issues$2bicssc 610 $a3D cell culture systems 610 $aacetaminophen 610 $aAlzheimer's disease 610 $aAlzheimer's disease-relevant tau species 610 $aanti-tau and anti-receptor bispecific monoclonal antibodies 610 $ablood-brain barrier 610 $ablood-brain barrier 610 $abrain biodistribution 610 $abrain cancer 610 $abrain targeted therapy 610 $acentral composite rotatable design 610 $acerebral open flow microperfusion 610 $acerebrospinal fluid microcirculation 610 $achemoattractant 610 $aclaudin-5 610 $aCNS drug delivery 610 $aconvection-enhanced delivery 610 $aCXCL 610 $aCXCR 610 $adelivery to brain 610 $adepression 610 $adiffuse midline glioma 610 $adrug delivery 610 $adrug delivery into the brain 610 $aelectrochemical biosensors 610 $aGB-13 610 $agene therapy 610 $aglioblastoma 610 $aglioblastoma multiforme 610 $aglycol chitosan 610 $ahigh-grade glioma 610 $ahyaluronidase 610 $aIL-13 610 $aIL-13R?2 610 $aIL13.E13K-PE4E 610 $aimmunotherapy 610 $aimmunotoxin 610 $aimproved memory 610 $ainteractions between A? and tau 610 $aintranasal delivery 610 $alaser 610 $aliposome 610 $amacromolecules 610 $amemory impairment 610 $amicrodialysis 610 $amicroparticles 610 $amovement impairment 610 $an/a 610 $ananoparticle 610 $ananoparticles 610 $ananostructured lipid carrier 610 $anaringenin 610 $anasal delivery system 610 $aneurosurgery 610 $anon-human primate 610 $anose to brain delivery 610 $aopioids 610 $aoptogenetics 610 $aParkinson's disease 610 $aphospholipid oily gel 610 $aPLGA 610 $apolyplexes 610 $apomegranate seed oil 610 $areceptor expression 610 $aseizure 610 $atargeted therapy 610 $atau clearance in microglia 610 $atau clearance in neurons 610 $atemporal-spatial pathological A? and tau distribution 610 $atight junction 610 $atolcapone 610 $atransendothelium based on receptor-mediated transcytosis 610 $aultrasound 615 7$aTechnology: general issues 700 $aSousa$b Fla?via$4edt$01323094 702 $aSousa$b Fla?via$4oth 906 $aBOOK 912 $a9910619467203321 996 $aBrain-Targeted Drug Delivery$93035376 997 $aUNINA